Australia Health

Neuren Pharmaceuticals (ASX:NEU) reported second-quarter DAYBUE net sales of US$125 million through partner Acadia Pharmaceuticals (NASDAQ:ACAD).

Biotechnology firm AdAlta (ASX:1AD) reported that a trial patient achieved two years of recurrence-free cancer survival.

Amplia Therapeutics (ASX:ATX) partnered with Eli Lilly & Company (NYSE:LLY) for a Phase 1b/2b trial starting in late 2026.

Neurotech International (ASX:NTI) has secured binding commitments to raise $4.5 million to advance its Phase 3 paediatric autism clinical trial.

Entropy Neurodynamics (ASX:ENP) has secured ethics approval for a Phase 1b/2a clinical trial evaluating drug TRP-8803 in 72 patients.

Regis Healthcare (ASX:REG) entered into a binding agreement to acquire the home care business of Royal Freemasons Homes of Victoria

4DMedical (ASX:4DX) reported operating revenue of $278 million as of June 30.

Mayne Pharma (ASX:MYX) reported $86.5 million in fourth-quarter revenue and $383.7 million in full-year revenue for fiscal year 2026.

Recce Pharmaceuticals (ASX:RCE) highlights a US$66.9 billion United States health strategy supporting antimicrobial resistance and clinical trials.

Dimerix (ASX:DXB) acquired a Phase 2-ready acute kidney injury candidate named DMX-652 for US$5 million.

Foresta Group Holdings (ASX:FGH) secured patent acceptance in Japan for its proprietary pine chemical extraction technology.

SomnoMed (ASX:SOM) announced Co-CEO Amrita Blickstead stepped down on July 27, leaving Karen Borg to lead the business globally.